155 related articles for article (PubMed ID: 8251098)
1. The role of the pharmacist in investigational AED trials.
Graves NM
Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098
[No Abstract] [Full Text] [Related]
2. Protocol design.
Wilensky AJ
Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
[No Abstract] [Full Text] [Related]
3. Obstacles encountered in designing antiepileptic drug trials.
French JA
Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107
[No Abstract] [Full Text] [Related]
4. Role of the Institutional Review Board in clinical trials.
Skolnick BE
Epilepsy Res Suppl; 1993; 10():193-200. PubMed ID: 8251097
[No Abstract] [Full Text] [Related]
5. Ethical considerations.
Treiman DM
Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
[No Abstract] [Full Text] [Related]
6. European investigational antiepilepsy drug trials.
Sussman NM
Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090
[No Abstract] [Full Text] [Related]
7. Sources of variability in clinical trials of new drugs for epilepsy.
Leppik IE
Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
[No Abstract] [Full Text] [Related]
8. Study population selection.
Treiman DM
Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088
[No Abstract] [Full Text] [Related]
9. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
Browne TR
Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
[No Abstract] [Full Text] [Related]
10. External influences on protocol design.
Spilker B
Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
[No Abstract] [Full Text] [Related]
11. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
12. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy.
McAuley JW; Chen AY; Elliott JO; Shneker BF
Epilepsy Behav; 2009 Jan; 14(1):113-7. PubMed ID: 18768168
[TBL] [Abstract][Full Text] [Related]
13. Patient recruitment and compliance issues in clinical trials.
Cramer JA
Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099
[No Abstract] [Full Text] [Related]
14. Preparing for an FDA audit.
Barnes D
Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
[No Abstract] [Full Text] [Related]
15. [The role of the Danish Medical Products Agency in clinical trials].
Simonsen AC
Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
[TBL] [Abstract][Full Text] [Related]
16. Fostering the relationship between the clinical research associate and the drug study coordinator.
Brodie MA
Epilepsy Res Suppl; 1993; 10():233-7. PubMed ID: 8251101
[No Abstract] [Full Text] [Related]
17. Visit management: reducing unnecessary paperwork.
Salzmann JK
Epilepsy Res Suppl; 1993; 10():223-31. PubMed ID: 8251100
[No Abstract] [Full Text] [Related]
18. Monitoring for adverse effects of antiepileptic drugs.
Camfield P; Camfield C
Epilepsia; 2006; 47 Suppl 1():31-4. PubMed ID: 17044823
[TBL] [Abstract][Full Text] [Related]
19. Tiagabine: new preparation. Refractory partial epilepsy: another alternative.
Prescrire Int; 1998 Aug; 7(36):99-101. PubMed ID: 10342943
[TBL] [Abstract][Full Text] [Related]
20. The impact of foreign data on a new drug application.
Galbraith H; Walker SD
Adv Neurol; 1998; 76():143-7. PubMed ID: 9408471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
